Journal of psychopharmacology (Oxford, England) · 2026
Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Songmin, Kim Min-Gul, Trott Mike, Siskind Dan, Kim Jae Hyun
Аннотация
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a potential treatment for antipsychotic-induced weight gain. This meta-analysis aimed to investigate the efficacy of GLP-1RAs on weight, body mass index (BMI), waist circumference, and visceral fat in patients receiving antipsychotics.
METHODS: We searched PubMed, Embase, the Cochrane Central, and APA PsycINFO through April 21, 2026, for randomized controlled trials (RCTs) of GLP-1RAs in patients treated with antipsychotics. Outcomes included weight, BMI, waist circumference, and visceral fat. Between-group mean differences (MDs) and their standard errors were used for meta-analyses. The risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. This study is registered with PROSPERO (CRD420251118829).
RESULTS: Nine RCTs including 595 participants were identified, of whom 294 received GLP-1RAs and 301 received placebo. Four studies reported visceral fat outcomes. GLP-1RAs significantly reduced body weight (MD -6.82 kg (95% confidence interval; CI -9.66 to -3.97), p < 0.0001), BMI (-2.23 kg/m2 (95% CI -3.15 to -1.30), p < 0.0001), waist circumference (-4.94 cm (95% CI -6.92 to -2.96), p < 0.0001), and visceral fat (-0.37 kg (95% CI -0.69 to -0.05), p = 0.0255) compared with placebo. The certainty of evidence was rated as moderate across all outcomes.
CONCLUSION: This meta-analysis demonstrates the benefit of GLP-1RAs in reducing body weight, BMI, waist circumference, and visceral fat. These findings support the clinical utility of GLP-1RAs as adjunctive treatments in patients with psychiatric disease and underscore the need for further trials with adiposity endpoints.
METHODS: We searched PubMed, Embase, the Cochrane Central, and APA PsycINFO through April 21, 2026, for randomized controlled trials (RCTs) of GLP-1RAs in patients treated with antipsychotics. Outcomes included weight, BMI, waist circumference, and visceral fat. Between-group mean differences (MDs) and their standard errors were used for meta-analyses. The risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. This study is registered with PROSPERO (CRD420251118829).
RESULTS: Nine RCTs including 595 participants were identified, of whom 294 received GLP-1RAs and 301 received placebo. Four studies reported visceral fat outcomes. GLP-1RAs significantly reduced body weight (MD -6.82 kg (95% confidence interval; CI -9.66 to -3.97), p < 0.0001), BMI (-2.23 kg/m2 (95% CI -3.15 to -1.30), p < 0.0001), waist circumference (-4.94 cm (95% CI -6.92 to -2.96), p < 0.0001), and visceral fat (-0.37 kg (95% CI -0.69 to -0.05), p = 0.0255) compared with placebo. The certainty of evidence was rated as moderate across all outcomes.
CONCLUSION: This meta-analysis demonstrates the benefit of GLP-1RAs in reducing body weight, BMI, waist circumference, and visceral fat. These findings support the clinical utility of GLP-1RAs as adjunctive treatments in patients with psychiatric disease and underscore the need for further trials with adiposity endpoints.